$KALV
KalVista Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024133673 Filed on December 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $16.61M
YoY Change -12.99%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $45.81M
YoY Change 54.01%
Operating Profit -$45.81M
YoY Change 54.01%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.543M
YoY Change 69.04%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$42.27M
YoY Change 52.87%
Net Earnings / Revenue
Basic Earnings Per Share -$0.91
Diluted Earnings Per Share -$0.91
COMMON SHARES
Basic Shares Outstanding 46.70M
Diluted Shares Outstanding 46.70M

Balance Sheet

Concept 2024 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $135.8M
YoY Change 31.6%
Cash & Equivalents $41.58M
Short-Term Investments $94.20M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $807.0K
Receivables
Other Receivables
Total Short-Term Assets $152.3M
YoY Change 18.4%
LONG-TERM ASSETS
Property, Plant & Equipment $2.039M
YoY Change -18.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $662.0K
YoY Change 96.44%
Total Long-Term Assets $8.564M
YoY Change -15.52%
TOTAL ASSETS
Total Short-Term Assets $152.3M
Total Long-Term Assets $8.564M
Total Assets $160.8M
YoY Change 15.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.198M
YoY Change 6.17%
Accrued Expenses $15.43M
YoY Change 31.79%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.16M
YoY Change 24.86%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $4.675M
YoY Change -28.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.16M
Total Long-Term Liabilities $4.675M
Total Liabilities $26.84M
YoY Change 10.46%
SHAREHOLDERS EQUITY
Retained Earnings -$552.4M
YoY Change 39.49%
Common Stock $689.1M
YoY Change 34.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $134.0M
YoY Change
Total Liabilities & Shareholders Equity $160.8M
YoY Change 15.92%

Cashflow Statement

Concept 2024 Q4
OPERATING ACTIVITIES
Net Income -$42.27M
YoY Change 52.87%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Entity Central Index Key
EntityCentralIndexKey
0001348911
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-10-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36830
dei Entity Registrant Name
EntityRegistrantName
KALVISTA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0915291
dei Entity Address Address Line1
EntityAddressAddressLine1
55 Cambridge Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 901E
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
999-0075
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
KALV
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49417986
CY2024Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41581000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31789000
CY2024Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
94195000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
178612000
CY2024Q4 kalv Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
11082000
CY2024Q2 kalv Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
8439000
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5409000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6850000
CY2024Q4 us-gaap Assets Current
AssetsCurrent
152267000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
225690000
CY2024Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2039000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2227000
CY2024Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5863000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6920000
CY2024Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
662000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
567000
CY2024Q4 us-gaap Assets
Assets
160831000
CY2024Q2 us-gaap Assets
Assets
235404000
CY2024Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5198000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9107000
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15429000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12398000
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1537000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1302000
CY2024Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22164000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22807000
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4675000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6015000
CY2024Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4675000
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6015000
CY2024Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43271501
CY2024Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43271501
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42521975
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42521975
CY2024Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
42000
CY2024Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
689087000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
679754000
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-552437000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-469726000
CY2024Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2701000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3488000
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
133992000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
206582000
CY2024Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
160831000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235404000
CY2024Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16610000
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19089000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43225000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38396000
CY2024Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29201000
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10657000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
46801000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20443000
CY2024Q4 us-gaap Operating Expenses
OperatingExpenses
45811000
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
29746000
us-gaap Operating Expenses
OperatingExpenses
90026000
us-gaap Operating Expenses
OperatingExpenses
58839000
CY2024Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-45811000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-29746000
us-gaap Operating Income Loss
OperatingIncomeLoss
-90026000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58839000
CY2024Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
1357000
CY2023Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
776000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3050000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1699000
CY2024Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
67000
CY2023Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1299000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
581000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-843000
CY2024Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2119000
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2619000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3685000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5016000
CY2024Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3543000
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2096000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7316000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5872000
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-42268000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-27650000
us-gaap Net Income Loss
NetIncomeLoss
-82710000
us-gaap Net Income Loss
NetIncomeLoss
-52967000
CY2024Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
166000
CY2023Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-419000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-328000
CY2024Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
651000
CY2023Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
440000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1715000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
832000
CY2024Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
649000
CY2023Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
595000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
966000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
909000
CY2024Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
168000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-574000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
787000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-405000
CY2024Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42100000
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28224000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81923000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53372000
CY2024Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2024Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
CY2024Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46695220
CY2024Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46695220
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34565955
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34565955
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46464099
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46464099
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34490090
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34490090
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
206582000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
3001000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3040000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-40443000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-128000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1064000
CY2024Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
317000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
172799000
CY2024Q4 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
294000
CY2024Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2999000
CY2024Q4 us-gaap Net Income Loss
NetIncomeLoss
-42268000
CY2024Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
166000
CY2024Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
651000
CY2024Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
649000
CY2024Q4 us-gaap Stockholders Equity
StockholdersEquity
133992000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
161025000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
204000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3254000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-25317000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
91000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
392000
CY2023Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
314000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
139335000
CY2023Q4 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
128000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3207000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-27650000
CY2023Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-419000
CY2023Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
440000
CY2023Q4 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
595000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
114446000
us-gaap Profit Loss
ProfitLoss
-82710000
us-gaap Profit Loss
ProfitLoss
-52967000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
451000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
390000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6039000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6461000
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
966000
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
909000
kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
-50000
kalv Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
-13000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
83000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
539000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-811000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
2321000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
4109000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1321000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-761000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4358000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
163000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3261000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2774000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79862000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46555000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
984000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
29537000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
87106000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
77917000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
129000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
158000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
203000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
85835000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48169000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3295000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
332000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3295000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
332000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
524000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-518000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9792000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1428000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31789000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56238000
CY2024Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41581000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57666000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
267000
CY2024Q1 kalv Number Of Participants
NumberOfParticipants
136
CY2024Q1 kalv Number Of Sites
NumberOfSites
66
CY2024Q1 kalv Number Of Countries
NumberOfCountries
20
CY2024Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-552400000
CY2024Q4 kalv Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
135800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. Accounting estimates and management judgments reflected in the condensed financial statements include: the accrual of research and development expenses, stock-based compensation, and operating lease liabilities. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2024Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
20655000
CY2024Q4 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
114850000
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
11143000
CY2024Q2 kalv Cash And Cash Equivalents And Marketable Securities Fair Value Disclosure
CashAndCashEquivalentsAndMarketableSecuritiesFairValueDisclosure
189755000
CY2024Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
92940000
CY2024Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1256000
CY2024Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2024Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
94195000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
178327000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
683000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
398000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
178612000
CY2024Q4 kalv Allowance For Credit Losses On Securities In Unrealized Loss Position Recognized
AllowanceForCreditLossesOnSecuritiesInUnrealizedLossPositionRecognized
0
CY2024Q2 kalv Allowance For Credit Losses On Securities In Unrealized Loss Position Recognized
AllowanceForCreditLossesOnSecuritiesInUnrealizedLossPositionRecognized
0
CY2024Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
46041000
CY2024Q4 kalv Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
38452000
CY2024Q4 kalv Available For Sale Securities Debt Maturities After Two Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughFourYearsFairValue
9702000
CY2024Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
94195000
CY2024Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6978000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6687000
CY2024Q4 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
4242000
CY2024Q2 kalv Accrued Research Expense Current
AccruedResearchExpenseCurrent
3416000
CY2024Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3930000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2042000
CY2024Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
253000
CY2024Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15429000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12398000
CY2024Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
807000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1585000
CY2024Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2756000
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2833000
CY2024Q4 us-gaap Interest Receivable And Other Assets
InterestReceivableAndOtherAssets
881000
CY2024Q2 us-gaap Interest Receivable And Other Assets
InterestReceivableAndOtherAssets
1409000
CY2024Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
965000
CY2024Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1023000
CY2024Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5409000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6850000
CY2024Q4 kalv Contractual Obligations Remaining Commitment Including Cancellation Provisions
ContractualObligationsRemainingCommitmentIncludingCancellationProvisions
19500000
kalv Amount Associated With Indemnification
AmountAssociatedWithIndemnification
0
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1060000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1765000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1607000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1602000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
769000
CY2024Q4 kalv Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
664000
CY2024Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7467000
CY2024Q4 kalv Lessee Operating Lease Liability Minimum Payments Interest Included In Payments
LesseeOperatingLeaseLiabilityMinimumPaymentsInterestIncludedInPayments
1255000
CY2024Q4 kalv Lessee Operating Lease Liability Present Value Of Net Minimum Payments
LesseeOperatingLeaseLiabilityPresentValueOfNetMinimumPayments
6212000
CY2024Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1537000
CY2024Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4675000
CY2024Q4 kalv Legally Binding Minimum Lease Payments
LegallyBindingMinimumLeasePayments
11200000
CY2024 kalv Annual Net Sales On Royalty Payments
AnnualNetSalesOnRoyaltyPayments
550000000
CY2024 us-gaap Revenues
Revenues
50000000
CY2024Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q4 kalv Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q4 kalv Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-133673-index-headers.html Edgar Link pending
0000950170-24-133673-index.html Edgar Link pending
0000950170-24-133673.txt Edgar Link pending
0000950170-24-133673-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kalv-20241031.htm Edgar Link pending
kalv-20241031.xsd Edgar Link pending
kalv-ex31_1.htm Edgar Link pending
kalv-ex31_2.htm Edgar Link pending
kalv-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
kalv-20241031_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable